Immunovant Inc. (IMVT)
NASDAQ: IMVTHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
IMVT stock chart
Technical analysisKey statistics
All statistics- Market cap
- $6.62B
- EPS (TTM)
- -$2.82
- Dividend yield
- None
- 52-week range
- 16.04 – 45.42
- Day range
- 31.58 – 32.75
- Volume / Avg
- 1.13M / 1.23M
- Beta
- —
- Shares outstanding
- 206.55M
52-week range
IMVT stock today
Immunovant (IMVT) closed at $32.04 on Oct 7, down 0.22% (-$0.07), versus the S&P 500's 0.22% decline. At this level, IMVT sits in the middle of its 52-week range of $16.04 to $45.42: 29.5% below the high, set on Aug 19, 2026 and 99.8% above the low. IMVT is up 26.0% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 98.9%.
Immunovant has posted a net loss over the last twelve months (EPS of -$2.82), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Immunovant
Company profileImmunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Eric Venker M.D., Pharm.D.
- Headquarters
- Durham, NC
- Employees
- 315
- IPO year
- 2019
- Website
- immunovant.com
Financial highlights
Full financialsImmunovant reported a net loss of $505.6 million, compared with a loss of $413.8 million a year earlier. Diluted earnings per share came in at -$2.77.
| Fiscal year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-505.61M | $-413.84M | $-259.34M | $-210.96M | $-156.73M |
| EPS (diluted) | $-2.77 | $-2.73 | $-1.88 | $-1.71 | $-1.43 |
Analyst forecast
ForecastConsensus (17 analysts)
buy
Avg. price target
$48.88+52.56%
- Strong buy 2
- Buy 11
- Hold 4
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Q1 2027)
- Aug 6, 2026
- EPS actual vs est.
- $-0.75 vs —
Immunovant peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| IOVAIovance Biotherapeutics Inc. | 12.92 | -0.35% | $5.85B | vs IMVT |
| KODKodiak Sciences Inc | 91.08 | -1.36% | $5.72B | vs IMVT |
| CGONCG Oncology Inc. | 62.38 | -1.98% | $5.53B | vs IMVT |
| SRRKScholar Rock Holding Corporation | 42.20 | -0.59% | $5.14B | vs IMVT |
| CRSPCRISPR Therapeutics AG | 52.35 | -3.06% | $5.06B | vs IMVT |
| KYMRKymera Therapeutics Inc. | 108.35 | +2.24% | $8.91B | vs IMVT |
| ADPTAdaptive Biotechnologies Corporation | 26.28 | -2.30% | $4.19B | vs IMVT |
| QGENQiagen N.V. | 44.79 | -1.88% | $9.25B | vs IMVT |
Indexes, lists and sector
Immunovant stock FAQ
What is Immunovant's stock price today?
IMVT last traded at $32.04 as of Oct 7, 4:00 PM EDT, down 0.22% on the day. Prices are delayed at least 15 minutes.
Who is Immunovant's CEO?
Dr. Eric Venker M.D., Pharm.D. is the chief executive officer of Immunovant Inc., which has about 315 employees.
What is the IMVT 52-week high?
The 52-week high for IMVT is $45.42 and the 52-week low is $16.04. The stock is currently 29.5% below its high.